Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Conditions
Keywords
lymphocyte activation gene (LAG), LAG-3, advanced solid tumor, metastatic solid tumor, relapsed/refractory DLCBL
Brief summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Interventions
BIOLOGICALINCAGN02385
INCAGN02385 administered as an intravenous infusion over 30 minutes.
Sponsors
Incyte Biosciences International Sàrl
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. * Disease progression after treatment with available therapies that are known to confer clinical benefit, or intolerant to treatment, or refuse noncurative standard treatment. There is no limit to the number of prior treatment regimens. * Participants with advanced or metastatic cervical cancer, MSI-high endometrial cancer, gastric cancer (including stomach and GEJ), esophageal cancer, hepatocellular carcinoma, melanoma (uveal melanoma excluded), Merkel cell carcinoma, mesothelioma, MSI-high colorectal cancer, NSCLC, ovarian cancer, SCCHN, SCLC, RCC, triple-negative breast cancer, and urothelial carcinoma, or alternative immunogenic tumor types with medical monitor approval. Participants with DLBCL may participate in Part 2 of the study. * Presence of measureable disease based on RECIST v1.1 for solid tumors or the Lugano classification for DLBCL. * Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies. * Eastern Cooperative Oncology Group performance status 0 or 1.
Exclusion criteria
* Laboratory and medical history parameters outside the protocol-defined range. * Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before study Day 1. * Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug. * Receipt of a live vaccine within 30 days of planned start of study drug. * Active autoimmune disease that required systemic treatment in the past. * Known active CNS metastases and/or carcinomatous meningitis. * Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry. See protocol-defined exceptions. * Evidence of active, noninfectious pneumonitis or history of interstitial lung disease. * Active infection requiring systemic therapy. * Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation. * Known history of HIV (HIV 1/2 antibodies). * Prior treatment with an anti-LAG-3 antibody for any indication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment-emergent adverse events (TEAEs) | Up to 12 months | TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax of INCAGN02385 | Up to 12 months | Time to maximum plasma concentration. |
| Cmin of INCAGN02385 | Up to 12 months | Minimum observed plasma concentration during the dosing interval. |
| AUC0-t of INCAGN02385 | Up to 12 months | Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration. |
| Objective response rate (ORR) in participants with advanced or metastatic solid tumors | Up to 12 months | Defined as the percentage of participants having complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Disease control rate (DCR) in participants with advanced or metastatic solid tumors | Up to 12 months | Defined as percentage of participants having CR, PR, or stable disease (SD) as best on-study response. |
| Cmax of INCAGN02385 | Up to 12 months | Maximum observed plasma concentration. |
| Progression-free survival (PFS) in participants with advanced or metastatic solid tumors | Up to 12 months | Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1 or death from any cause if occurring sooner than progression. |
| ORR in participants with diffuse large B-cell lymphoma (DLBCL) | Up to 12 months | Defined as the percentage of participants with a CR/complete metabolic response (CMR) or PR/partial metabolic response (PMR) per the Lugano Classification. |
| DOR in participants with DLBCL | Up to 12 months | Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression per radiographic disease assessment or death from any cause among participants who achieve an objective response. |
| PFS in participants with DLBCL | Up to 12 months | Defined as the time from the date of the first dose of study drug until the earliest date of disease progression per radiographic disease assessment or death from any cause if occurring sooner than progression. |
| Duration of response (DOR) in participants with advanced or metastatic solid tumors | Up to 12 months | Defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression per RECIST v1.1 or death from any cause, if occurring sooner than progression. |
Countries
United States
Outcome results
None listed